NURPF Company Profile and Key Details

PNK : NURPF

Neuren Pharmaceuticals

$14.00

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Neuren Pharmaceuticals Limited (NURPF) stock remained unchanged at $15.76 a share on OTC. The stock opened at $15.76, fluctuating between $15.76 to $15.76 during the session.

Stock Snapshot

15.76

Prev. Close

Market Cap

15.76

Day Low

149.55

P/E Ratio

0.10538

EPS (TTM)

2.18

Cash Flow per Share

15.76

Open

126.77M

Number of Shares

15.76

Day High

86.35%

Free Float in %

1.61

Book Value

400

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 15, 2026	16.10	16.10	15.76	15.76	400
Sep 02, 2026	16.10	16.10	16.10	16.10	100
Aug 31, 2026	15.01	16.01	15.01	16.01	300
Aug 27, 2026	15.51	16.24	15.51	16.24	432
Aug 20, 2026	15.51	15.51	15.51	15.51	75
Aug 18, 2026	15.51	15.51	15.51	15.51	19.35K
Aug 17, 2026	16.20	16.20	16.20	16.20	1.5K
Aug 11, 2026	16.50	17.25	16.50	16.77	575
Aug 10, 2026	16.00	16.00	16.00	16.00	4.47K
Aug 06, 2026	15.00	15.00	15.00	15.00	1.6K
Jun 30, 2026	12.00	13.46	11.50	13.46	410
Jun 26, 2026	8.90	9.27	8.75	9.27	700
Jun 18, 2026	8.69	8.69	8.69	8.69	200
Jun 16, 2026	8.48	8.48	8.48	8.48	446
May 11, 2026	9.25	9.25	8.88	8.88	750
Apr 30, 2026	7.83	7.83	7.83	7.83	1
Apr 14, 2026	8.82	8.82	8.82	8.82	2K
Mar 17, 2026	8.22	8.22	8.22	8.22	100
Feb 23, 2026	8.53	8.53	8.53	8.53	2.01K
Feb 10, 2026	9.86	9.86	9.86	9.86	100

Contact Details

Hawthorn East, VIC 3123

Australia

https://www.neurenpharma.com 613 909 20480

About Company

Neuren Pharmaceuticals Limited is a biopharmaceutical company specializing in the development of treatments for neurological conditions. Their leading therapeutic compound, trofinetide, is currently undergoing pivotal (Phase III) clinical trials for Rett syndrome, and has also successfully completed Phase II trials targeting Fragile X syndrome. The company is also progressing NNZ-2591, which has finished its initial human trials (Phase I) for a spectrum of rare neurodevelopmental disorders, including Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Willi syndromes. In addition to its drug pipeline, Neuren provides development-related services and possesses investments in loan-backed shares. The firm was established in 2001 and operates from its base in Camberwell, Australia.

Stock Peers

LZAGF

-5-0.92%

Lonza Group AG$541.00 GNMSF

Genmab A/S$268.61 CMXHF

CSL Limited$192.00 CSLLY

0.75+0.79%

CSL Limited$95.35 UCBJY

-0.06-0.08%

UCB SA$73.15 LZAGY

-0.33-0.61%

Lonza Group AG$53.87 PHMMF

4.3+16.01%

Pharma Mar, S.A.$31.15 BVNKF

Bavarian Nordic A/S$21.20 GRTX

1.53+9.80%

Galera Therapeutics, Inc.$17.15 TLPPF

Telix Pharmaceuticals Limited$11.00

Frequently Asked Questions

What is the current Neuren Pharmaceuticals Limited (NURPF) stock price?

Neuren Pharmaceuticals Limited (OTC: NURPF) stock price is $15.76 in the last trading session. During the trading session, NURPF stock reached the peak price of $15.76 while $15.76 was the lowest point it dropped to. The percentage change in NURPF stock occurred in the recent session was 0% while the dollar amount for the price change in NURPF stock was $0.00.

NURPF's industry and sector of operation?

The OTC listed NURPF is part of Biotechnology industry that operates in the broader Healthcare sector. Neuren Pharmaceuticals Limited designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of NURPF?

Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A.
Chief Executive Officer, MD & Executive Director
Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons)
Chief Executive Officer, MD & Director
Mr. Lawrence Glass
Chief Science Officer
Ms. Lauren Frazer C.A.
Chief Financial Officer & Company Sec.
Dr. Liza A. Squires M.D.
Chief Medical Officer
Mr. Gerry Zhao
Vice President of Corporation Devel.
Mr. Lawrence Glass BA (Biology)
Chief Science Officer

How NURPF did perform over past 52-week?

NURPF's closing price is 126.9% higher than its 52-week low of $7.70 where as its distance from 52-week high of $17.25 is -18.63%.

How many employees does NURPF have?

Number of NURPF employees currently stands at 8.

Link for NURPF official website?

Official Website of NURPF is: https://www.neurenpharma.com

How do I contact NURPF?

NURPF could be contacted at phone 613 909 20480 and can also be accessed through its website. NURPF operates from Suite 1.01, 117 Camberwell Road, Hawthorn East, VIC 3123, Australia.

How many shares of NURPF are traded daily?

NURPF stock volume for the day was 400 shares. The average number of NURPF shares traded daily for last 3 months was 486.

What is the market cap of NURPF currently?

The market value of NURPF currently stands at $2.00B with its latest stock price at $15.76 and 126.77M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	8
Beta	1.59
Sales or Revenue	$231.93M
5Y Sales Change%	11.921%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	8
Beta	1.59
Sales or Revenue	$231.93M
5Y Sales Change%	11.921%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

NURPF Company Profile and Key Details

Neuren Pharmaceuticals

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Company Overview

Dividend & Fair Value

Price Forecast & Outlook

Key Takeaways

Valuation Metrics